Deans' stroke musings: PACIFIC-Stroke: Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following Acute Non-Cardioembolic Ischemic Stroke

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, May 23, 2021

PACIFIC-Stroke: Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following Acute Non-Cardioembolic Ischemic Stroke

No clue but I guess you can look in here for a reference to BAY 2433334.

Factor XI as a Target for New Anticoagulants

The latest here:

PACIFIC-Stroke: Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following Acute Non-Cardioembolic Ischemic Stroke

PACIFIC-Stroke is a randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic ischemic stroke.

Primary outcome measures:

Number of participants with symptomatic ischemic stroke or covert brain infarcts detected by Magnetic resonance imaging (MRI). Baseline up to 6 months.
Time from randomization to first occurrence of International Society on Thrombosis and Hemostasis (ISTH) major bleeding and clinically relevant non-major (CRNM) bleeding . Baseline up to 12 months.